Abstract:Fenofibrate, as a lipid-lowering drug, has been reported to have a protective effect on the retina independent with plasma lipid levels. This study aimed to investigate that the ameliorative effects of fenofibrate on systemic and retinal inflammation, as well as gut microbiota dysbiosis in high-fat diet (HFD)-induced mice. C57BL/6J mice were randomly allocated into four groups: standard diet (SD) group; HFD group; SD plus fenofibrate (SD_ Fe) group; HFD plus fenofibrate (HFD_ Fe) group. After successfully establishing models (5 months), indicators associated with lipid, gut barrier, inflammation and gut microbiota were investigated. Our results showed that supplementing the HFD with fenofibrate decreased body weight gain, alleviated dyslipidemia and reversed the downregulation of short-chain fatty acid (SCFAs) in serum, retina and feces. Fenofibrate ameliorated intestinal barrier function damage in HFD-induced mice. Fenofibrate coadministration inhibited the levels of inflammatory factor and lipopolysaccharide (LPS) in the serum and attenuated inflammatory response in the retina of HFD-induced mice. Systemic LPS was positively correlated with a series of inflammatory factors in serum and retina, respectively. Fenofibrate supplementation down-regulated the abundances of LPS-associated bacteria in HFD mice, including Firmicutes and Proteobacteria at the phylum level, Desulfovibrionaceae at the family level, as well as unclassified_ Desulfovibrionaceae , Acetatifactor , Flavonifractor , Oscillibacter and Anaerotruncus at the genus level. However, fenofibrate treatment up-regulated the abundances of SCFA-associated bacteria in HFD mice, including Bacteroidetes at the phylum level, Porphyromonadaceae at the family level, as well as unclassified_Porphyromonadaceae , Barnesiella , Alloprevotella and Bifidobacterium at the genus level. In conclusion, our results confirmed fenofibrate could attenuate HFD-induced systemic and retinal inflammation, accompanying with restoration of intestinal barrier damage and modulation of gut microbiota/metabolites. This work provided an explanation for the ameliorative effects of fenofibrate on HFD-induced systemic and retinal inflammation might be partially related with the modulation of gut microbiota and its metabolites.

PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate.

GC-MS metabolomics on PPARα-dependent exacerbation of colitis.

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis

Modulation of LPS-mediated Inflammation by Fenofibrate Via the TRIF-dependent TLR4 Signaling Pathway in Vascular Smooth Muscle Cells.

Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice

Fenofibrate Attenuates Hepatic Fibrosis by PPAR-Α and TGF-β1/Smad Signaling Pathway Via Modulating Autophagy and Oxidative Stress

Ppar Alpha Activator Fenofibrate Modulates Angiotensin Ii-Induced Inflammatory Responses in Vascular Smooth Muscle Cells Via the Tlr4-Dependent Signaling Pathway

PPARα Agonist Fenofibrate Attenuates TNF-α-induced CD40 Expression in 3T3-L1 Adipocytes Via the SIRT1-dependent Signaling Pathway

Fenofibrate Inhibited the Differentiation of T Helper 17 Cells in Vitro

Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice

PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway

PPARα activation protects against cholestatic liver injury

Fenofibrate Enhances the in Vitro Differentiation of Foxp3+ Regulatory T Cells in Mice

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

PPARα-UGT Axis Activation Represses Intestinal FXR-FGF15 Feedback Signalling and Exacerbates Experimental Colitis

IL-10-Dependent and -Independent Mechanisms Are Involved in the Cardiac Pathology Modulation Mediated by Fenofibrate in an Experimental Model of Chagas Heart Disease

Fenofibrate promotes PPARα-targeted recovery of the intestinal epithelial barrier at the host-microbe interface in dogs with diabetes mellitus

The Protective Effect of Fenofibrate Against TNF-α-Induced CD40 Expression through SIRT1-Mediated Deacetylation of NF-κB in Endothelial Cells

The Peroxisome Proliferator-activated Receptor Α (pparα) Regulates Bile Acid Biosynthesis*